QUINCE THERAPEUTICS INC (QNCX)
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
$31.32+2.52%
Close 2026-09-04 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
QuarterlyIQ Insights · QNCX
Income statement, balance sheet, and cash flow — annual and quarterly history, as reported.
Figures in millions of None, except per-share and ratios.
| TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | |
|---|---|---|---|---|---|---|---|---|
| Operating Expenses & Income | ||||||||
| R&D Expenses | 33.0 | 35.4 | 18.6 | 9.4 | 25.2 | 60.8 | 61.3 | 30.2 |
| Operating Income | (127.2) | (58.1) | (57.3) | (34.6) | (52.0) | (90.3) | (78.9) | (39.2) |
| Earnings from Continuing Operations | ||||||||
| Interest Expense | — | — | — | — | — | — | — | 1.0 |
| Interest & Investment Income | 1.3 | 1.2 | 2.9 | 3.5 | 1.1 | 0.6 | 2.0 | — |
| Asset Writedown | — | — | — | 0.0 | — | 0.0 | — | — |
| EBT, Incl. Unusual Items | — | (80.8) | (56.7) | (31.6) | (51.9) | (89.9) | (76.8) | — |
| Income Tax Expense | (2.2) | 3.2 | 0.1 | (0.2) | (0.3) | 0.0 | 0.0 | — |
| Net Income | ||||||||
| Net Income | (92.5) | (84.0) | (56.8) | (31.4) | (51.7) | (89.9) | (76.8) | (37.0) |
| Per Share | ||||||||
| Basic EPS | (15.08) | (1.68) | (1.31) | (0.84) | (1.54) | (3.03) | — | — |
| Diluted EPS | (15.08) | (1.68) | (1.31) | (0.84) | (1.54) | (3.03) | — | — |
| Basic Weighted Avg Shares | 6.1 | 50.1 | 43.3 | 37.2 | 33.5 | 29.7 | — | — |
| Diluted Weighted Avg Shares | 6.1 | 50.1 | 43.3 | 37.2 | 33.5 | 29.7 | — | — |
| Supplemental | ||||||||
| EBITDA | — | (57.9) | (57.1) | (34.3) | (51.8) | (90.0) | (78.6) | (39.0) |
| EBIT | (127.2) | (58.1) | (57.3) | (34.6) | (52.0) | (90.3) | (78.9) | (39.2) |
| Effective Tax Rate | — | — | — | 0.6% | 0.5% | 0.0% | 0.0% | — |
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.